Compare GTIM & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | NOTV |
|---|---|---|
| Founded | 1987 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.8M |
| IPO Year | 2013 | 1997 |
| Metric | GTIM | NOTV |
|---|---|---|
| Price | $1.21 | $0.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 20.4K | ★ 377.8K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ 0.02 | N/A |
| Revenue | $142,315,000.00 | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | $59.50 | ★ N/A |
| Revenue Growth | 3.01 | ★ 511.19 |
| 52 Week Low | $1.10 | $0.24 |
| 52 Week High | $2.24 | $3.31 |
| Indicator | GTIM | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 38.16 |
| Support Level | $1.16 | $0.26 |
| Resistance Level | $1.29 | $0.46 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 88.89 | 10.95 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.